Enhancement in a brain glioma model: A comparison of half‐dose gadobenate dimeglumine versus full‐dose gadopentetate dimeglumine at 1.5 and 3 T

Abstract

Improved r1 relaxivity with gadobenate dimeglumine does not produce adequate half-dose contrast-enhancement relative to full-dose gadopentetate dimeglumine.

Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI

“…An additional dose of contrast medium to achieve a higher contrast-to-noise ratio (CNR) makes this protocol challenging for patients with various renal disorders where conditions, such as nephrogenic systemic fibrosis, may occur with higher and/or multiple contrast medium doses. 21 The requirement for high contrast medium dosage decreases when using 3 T MRI systems compared with 1.5 T systems due to improved T1 relaxivity of contrast agents and with the availability of higher relaxivity contrast agents, such as gadobenate dimeglumine (Gd-BOPTA). 21e28 In the first-pass analysis as done in perfusion MRI, a contrast agent with higher relaxivity, such as Gd-BOPTA, using 3 T MRI will produce a higher signal-to-noise ratio (SNR) using a single dose of contrast medium compared with other similar agents with lower relaxivity.…”

Feasibility of using half‐dose Gd‐BOPTA for delayed gadolinium‐enhanced MRI of cartilage (dGEMRIC) at the knee, compared with standard‐dose Gd‐DTPA

“…The finding of lower, but not significantly different values, in normal cartilage of healthy volunteers, but significantly lower values in damaged cartilage, of Gd‐BOPTA may be explained in part by differences in the effect of the different relaxivity of Gd‐BOPTA and Gd‐DTPA in areas with differing GAG content. Gd‐BOPTA has a relaxivity of 6.3 L mmol ‐1 s ‐1 vs. 3.3 L mmol ‐1 s ‐1 for Gd‐DTPA . In GAG‐rich areas, a comparably low amount of contrast agent is present; hence, the impact of the higher relaxivity of Gd‐BOPTA is also low.…”

“…However, complete transferability of T 1 ‐values is not easily expected even in a dose‐finding study, since the exact T 1 ‐value after contrast administration is a complex process, with many contributors, including molecular structure, concentration, field strengths, and differences in GAG content in different cartilage areas . We therefore presented conversion factors of Gd‐DTPA and Gd‐BOPTA for dGEMRIC in healthy cartilage, to provide insight into the relation at different timepoints and therefore different amounts of contrast‐agent within the cartilage.…”